Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Eli Lilly and Company (LLY) — XLV Health Care · S&P 500 Profile |禮來公司介紹

health-careS&P500SPX Top25xlvxlv-top-25
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Eli Lilly and Company (LLY) — Business, History & S&P 500 Profile |禮來公司介紹

Eli Lilly company profile · tirzepatide · business segments · history · financial snapshot · S&P 500 rank #11 · 禮來公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Oct 21, 2026 (ET) close
Financials: FY2025 (ended Dec 31, 2025)
MARKET CAP
$1,120B
Oct 16, 2026 · #1 in Health Care by market cap
S&P 500 WEIGHT
1.60%
Rank #11 · Oct 21, 2026 (Slickcharts)
FY2025 REVENUE
$65.18B
+45% YoY · record year
FY2025 NET INCOME
$20.64B
Net margin 31.7%

SNAPSHOT

TickerLLY (NYSE)
CompanyEli Lilly and Company
GICS sector / industryHealth Care (XLV) / Pharmaceuticals
S&P 500 rank (by weight)#11 · 1.60% (Oct 21, 2026)
Sector rank (by market cap)#1 in Health Care (Oct 16, 2026)
HeadquartersIndianapolis, Indiana
FoundedMay 10, 1876, Indianapolis, Indiana (incorporated 1901)
CEODavid A. Ricks (chair, president & CEO since 2017)
Employees≈50,000 — Dec 31, 2025, FY2025 10-K
Market cap$1,120B (Oct 16, 2026)
SEC filingsEDGAR — CIK 0000059478

WHAT IT DOES

Eli Lilly and Company — Lilly — is a research-based global pharmaceutical company headquartered in Indianapolis, Indiana. It discovers, develops, manufactures and sells branded prescription medicines in approximately 90 countries, with offices, production and research facilities in 36 countries. Founded in 1876, it employs roughly 50,000 people and is the world's largest drugmaker by revenue.

The money comes from patent-protected branded drugs. In FY2025, net product sales were $60.96B (93.5% of revenue); collaboration and other revenue — profit-sharing, royalties, milestones — added $4.22B (6.5%). The engine is a single molecule: tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea. The two brands did $36.5B combined in FY2025 — 56% of the entire company.

Beyond tirzepatide, the portfolio spans oncology (Verzenio for breast cancer), immunology (Taltz, Omvoh, Ebglyss), neuroscience (Kisunla for early Alzheimer's, Emgality for migraine) and a legacy diabetes franchise (Trulicity, insulins). The United States was 66.7% of FY2025 revenue and Europe 17.7%. The flywheel is R&D reinvestment — $13.3B in FY2025, about one-fifth of revenue, funding 36 active Phase III programs — plus a manufacturing buildout of more than $55B committed since 2020 to keep the incretin supply ahead of demand.

BUSINESS SEGMENTS — FY2025 PRODUCT REVENUE

ProductRevenueShareYoY
Mounjaro (tirzepatide, type 2 diabetes)$22.97B35.2%+99%
Zepbound (tirzepatide, obesity)$13.54B20.8%+175%
Verzenio (abemaciclib, breast cancer)$5.72B8.8%+8%
Trulicity (dulaglutide, type 2 diabetes)$4.28B6.6%−19%
Taltz (ixekizumab, immunology)$3.56B5.5%+9%
Jardiance family (empagliflozin, with Boehringer Ingelheim)$3.43B5.3%+3%
Other cardiometabolic health (incl. insulins)$4.01B6.1%−10%
Other oncology$3.65B5.6%+6%
Other immunology$1.68B2.6%+49%
Neuroscience$1.39B2.1%−6%
Other$0.94B1.4%+4%
Total$65.18B100%+45%
Source: Lilly FY2025 Form 10-K product revenue disclosures (SEC-filing-based compilation; Mounjaro/Zepbound totals cross-checked with the Q4 2025 earnings release). Lilly reports revenue by product rather than by segment. Net product sales were $60.96B (93.5% of revenue); collaboration & other revenue $4.22B (6.5%). Lilly defines Key Products as Ebglyss, Jaypirca, Kisunla, Mounjaro, Omvoh, Verzenio and Zepbound.

Tirzepatide (Mounjaro + Zepbound) is the franchise — a dual GIP/GLP-1 receptor agonist, $36.5B in FY2025 and 56% of revenue. Mounjaro (type 2 diabetes, launched 2022) holds more than 55% of new US diabetes prescriptions; Zepbound (obesity, approved Nov 2023) holds nearly 70% of new US branded obesity prescriptions, with lower-priced vials now about one-third of its scripts.

Verzenio (CDK4/6 inhibitor for breast cancer) is the oncology anchor at $5.72B and still growing. Trulicity, the older once-weekly GLP-1, is fading as tirzepatide cannibalizes it — down 19% in FY2025 to $4.28B.

Taltz (immunology) and the Jardiance family (co-marketed with Boehringer Ingelheim) are steady mid-single-digit growers. The "other" buckets carry the next wave: recently launched Omvoh and Ebglyss in immunology, Jaypirca in oncology, and Kisunla — the anti-amyloid Alzheimer's drug — in neuroscience.

HISTORY

YearMilestone
1876Colonel Eli Lilly, a Civil War veteran and pharmaceutical chemist, founds the drug business in Indianapolis (incorporated as Eli Lilly and Company in 1901)
1923First company to mass-produce insulin (Iletin), working with the University of Toronto researchers
1955First to mass-produce the Salk polio vaccine
1982Humulin approved — the first recombinant-DNA human insulin and the first biotech drug
1987Prozac (fluoxetine) approved — becomes a blockbuster antidepressant
1996Zyprexa (olanzapine) approved for schizophrenia and bipolar disorder
2003Cialis (tadalafil) approved — becomes a major erectile-dysfunction franchise
2008Acquires ImClone Systems for ≈$6.5B, gaining the cancer drug Erbitux
2014Acquires Novartis's animal health business for $5.4B, folded into Elanco
2017David Ricks becomes CEO
2018Elanco animal health business IPO (September)
2019Acquires Loxo Oncology for approximately $8.0B (February; $235.00 per share in cash, announced Jan 7, 2019); completes the Elanco split-off (March)
2022Mounjaro (tirzepatide) FDA-approved for type 2 diabetes (May)
2023Zepbound approved for chronic weight management (November, US)
2024Kisunla (donanemab) approved for early Alzheimer's (July, US); Lilly becomes the world's most valuable drugmaker
2025Tirzepatide franchise reaches $36.5B (56% of revenue); market cap touches $1T (November), the first health-care company to do so
2026Foundayo (orforglipron) — the first oral small-molecule GLP-1 — FDA-approved for obesity (April); record Q2 revenue of $22.97B (+48%); FY2026 guidance raised to $85–87B; announces a $3.5B injectables plant in Pennsylvania (October)

COMPETITIVE POSITION

  • The world's largest drugmaker by revenue — FY2025 revenue of $65.2B edged Merck's $65.0B, and the tirzepatide franchise alone ($36.5B) outsells most mid-cap pharma companies outright (Drug Discovery Trends, Feb 2026).
  • One half of the incretin duopoly — Lilly and Novo Nordisk own the GLP-1 market. Zepbound holds nearly 70% of new US branded obesity prescriptions and Mounjaro more than 55% of new US type 2 diabetes prescriptions (Lilly Q4 2025 earnings call).
  • Patent runway — the main US compound patent on tirzepatide runs to 2036; generic makers filed early-copy applications in July 2026 and Lilly is suing to defend them.
  • Next-wave pipeline — orforglipron (Foundayo, approved April 2026) is the first oral small-molecule GLP-1; retatrutide (triple agonist) and eloralintide lead 36 active Phase III programs.
  • Manufacturing as moat — more than $55B committed to capacity since 2020; US list-price cuts on vials and the LillyDirect channel widen access while pressuring realized prices.
  • Competition set — Novo Nordisk (Wegovy/Ozempic; oral Wegovy FDA-approved December 2025), Amgen (MariTide), Pfizer, Viking Therapeutics, Structure Therapeutics, Roche/Zealand, plus compounding pharmacies selling tirzepatide copies.

FINANCIAL SNAPSHOT — FY2025

Revenue$65.18B (+45% YoY; FY2024 $45.04B)
Gross profit / margin$54.1B · 83.0%
Operating income$26.30B · 40.4% margin
Net income$20.64B · 31.7% margin (+95% YoY)
Diluted EPS$22.95 reported · $24.21 non-GAAP (+86%)
R&D expense$13.3B (20.4% of revenue)
Operating cash flow$16.81B (FY2024 $8.82B)
Free cash flow≈$6.0B (OCF $16.81B − capex $10.85B)
Cash & equivalents$7.27B (Dec 31, 2025)
Total debt≈$42.5B — net debt position (debt/equity ≈1.6×)
Dividends$6.00/share (+15% YoY) · $5.38B paid
Latest quarter (Q2 2026, ended Jun 30, 2026)Revenue $22.97B (+48% YoY) · net income $7.10B · diluted EPS $7.94 (non-GAAP $8.38) · gross margin ≈86%
Source: Lilly FY2025 Form 10-K (filed February 2026; FY ended Dec 31, 2025) via S&P Capital IQ/FT Markets and Alpha Spread 10-K line items; Q2 2026 earnings release (August 5, 2026). Gross margin 83.0% reflects favorable product mix, partly offset by lower realized prices.

KEY RISKS

  • Single-molecule concentration — tirzepatide is 56% of revenue. A safety signal, supply disruption or pricing shock to this one molecule hits more than half the company.
  • Patent cliff and generic challenges — the main US compound patent runs to 2036, but generic makers already filed early-copy applications in July 2026; Lilly is litigating, and any loss would open the crown jewel early.
  • Pricing pressure — US realized prices are falling (expected low-to-mid-teens decline in 2026); the Medicare/Medicaid obesity-access agreement targets $50/month out-of-pocket, and PBMs extract growing rebates.
  • Novo Nordisk and the next wave — oral Wegovy was FDA-approved in December 2025; Amgen's MariTide, Pfizer, Viking and others are chasing the same obesity market with differentiated mechanisms.
  • Compounding pharmacies — copycat tirzepatide formulations compete on price outside the branded channel and have drawn FDA and Lilly enforcement attention.
  • Trulicity erosion — the legacy diabetes franchise fell 19% in FY2025 as tirzepatide cannibalizes it, with biosimilar risk as patents age.
  • Manufacturing execution — the $55B+ capacity program consumes most operating cash flow (capex $10.85B in FY2025); delays or cost overruns cap the upside the market is paying for.

WHY IT MATTERS FOR THE S&P 500

Lilly is the index's #11 constituent at a 1.60% weight (Oct 21, 2026) — a 1% move in LLY moves the S&P 500 by roughly 1.6 basis points, and it is the single largest name in the Health Care sector by market cap ($1,120B, Oct 16, 2026). In an index dominated by technology, Lilly is the defensive-growth anchor of health care: the sector's bellwether, with a low beta (≈0.43) and the market's purest exposure to the obesity-drug cycle.

For index and options traders: Lilly's quarterly prints (late January / April / July / October) read as a verdict on GLP-1 demand, pricing and supply — moving XLV and the broader health-care complex — and its prescription-share data versus Novo Nordisk is the highest-frequency read on the incretin duopoly available to the market.

SOURCES & METHODOLOGY

Financials, products, employees, cash/debtLilly FY2025 Form 10-K (filed February 2026; fiscal year ended Dec 31, 2025); line items via S&P Capital IQ (FT Markets) and Alpha Spread
Product revenue splitFY2025 10-K product disclosures (SEC-filing-based compilation); Mounjaro/Zepbound totals cross-checked with the Q4 2025 earnings release (Feb 4, 2026)
Latest quarter (Q2 2026)Lilly Q2 2026 earnings release (August 5, 2026); quarter ended Jun 30, 2026
Index weight & rankSlickcharts S&P 500 weights, Oct 21, 2026 close (assignment baseline)
Market cap & sector rankOct 16, 2026 snapshot (SPXSet Top-25 dataset; assignment baseline)
Prescription share, pipeline, guidanceLilly Q4 2025 earnings call transcript (finviz); FY2026 guidance $85–87B revenue via TipRanks (Oct 20, 2026)
History & company factsLilly 10-K/10-Q/8-K filings (via findstockfast); Wikipedia company page (facts cross-checked against filings)
LogoSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics.

Price Chart — 10-Year Monthly Candles

Lilly

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

股票代號LLY(NYSE)
公司Eli Lilly and Company(禮來公司)
GICS 板塊/行業醫療健康(XLV)/製藥
標普500排名(按權重)#11 · 1.60%(2026年10月21日)
板塊內排名(按市值)醫療健康 #1(2026年10月16日)
總部印第安納州印第安納波利斯
成立1876年5月10日,印第安納波利斯(1901年註冊為公司)
執行長David A. Ricks(2017年起任董事長、總裁兼執行長)
員工約50,000名——2025年12月31日,FY2025 10-K
市值$1,120B(1.12兆美元,2026年10月16日)
SEC 申報EDGAR — CIK 0000059478

業務概覽

禮來(Eli Lilly and Company)是一家以研發為本的全球製藥公司,總部位於印第安納州印第安納波利斯。公司發現、開發、生產並銷售品牌處方藥,業務遍及約 90 個國家,在 36 個國家設有辦公室、生產與研發設施。創立於 1876 年,員工約 50,000 名,是全球營收最高的製藥公司。

收入來自受專利保護的品牌藥。FY2025 淨產品銷售 $60.96B(609.6億美元,佔營收 93.5%);合作與其他收入——利潤分成、權利金、里程碑款——為 $4.22B(42.2億美元,佔 6.5%)。增長引擎是單一分子:替爾泊肽(tirzepatide),以 Mounjaro 治二型糖尿病、以 Zepbound 治肥胖與阻塞性睡眠呼吸中止。兩品牌 FY2025 合計 $36.5B(365億美元)——佔全公司 56%。

替爾泊肽之外,產品線涵蓋腫瘤(乳癌藥 Verzenio)、免疫(Taltz、Omvoh、Ebglyss)、神經科學(早期阿茲海默症藥 Kisunla、偏頭痛藥 Emgality),以及傳統糖尿病業務(Trulicity、胰島素)。美國佔 FY2025 營收 66.7%,歐洲 17.7%。飛輪是研發再投入——FY2025 研發 $13.3B(133億美元,約佔營收兩成),支撐 36 項三期臨床試驗——以及自 2020 年以來承諾逾 $55B(550億美元)的產能擴建,讓腸泌素產能跑在需求前面。

業務板塊 — FY2025 產品營收

產品營收佔比同比
Mounjaro(替爾泊肽,二型糖尿病)$22.97B(229.7億美元)35.2%+99%
Zepbound(替爾泊肽,肥胖)$13.54B(135.4億美元)20.8%+175%
Verzenio(abemaciclib,乳癌)$5.72B(57.2億美元)8.8%+8%
Trulicity(dulaglutide,二型糖尿病)$4.28B(42.8億美元)6.6%−19%
Taltz(ixekizumab,免疫)$3.56B(35.6億美元)5.5%+9%
Jardiance 系列(empagliflozin,與勃林格殷格翰合作)$3.43B(34.3億美元)5.3%+3%
其他心臟代謝(含胰島素)$4.01B(40.1億美元)6.1%−10%
其他腫瘤$3.65B(36.5億美元)5.6%+6%
其他免疫$1.68B(16.8億美元)2.6%+49%
神經科學$1.39B(13.9億美元)2.1%−6%
其他$0.94B(9.4億美元)1.4%+4%
合計$65.18B(651.8億美元)100%+45%
來源:禮來 FY2025 Form 10-K 產品營收披露(SEC 申報為本的彙整;Mounjaro/Zepbound 總額已與 2025 年第四季財報交叉核對)。禮來按產品而非按板塊申報營收。淨產品銷售 $60.96B(609.6億美元,佔營收 93.5%);合作與其他收入 $4.22B(42.2億美元,佔 6.5%)。禮來定義的關鍵產品為 Ebglyss、Jaypirca、Kisunla、Mounjaro、Omvoh、Verzenio 與 Zepbound。

替爾泊肽(Mounjaro+Zepbound)就是整家公司——雙 GIP/GLP-1 受體促效劑,FY2025 營收 $36.5B(365億美元),佔 56%。Mounjaro(二型糖尿病,2022 年上市)拿下美國新增糖尿病處方逾 55%;Zepbound(肥胖,2023 年 11 月獲批)在美國新增品牌肥胖藥處方市佔近七成(70%),較便宜的小瓶裝已佔其處方約三分之一。

Verzenio(CDK4/6 抑制劑,乳癌)是腫瘤支柱,$5.72B(57.2億美元)仍在成長。Trulicity 是上一代每週一次 GLP-1,正被替爾泊肽蠶食——FY2025 下滑 19% 至 $4.28B(42.8億美元)。

Taltz(免疫)與 Jardiance 系列(與勃林格殷格翰合銷)是穩健的中個位數成長業務。「其他」項藏著下一波:免疫新藥 Omvoh、Ebglyss,腫瘤藥 Jaypirca,以及神經科學的抗類澱粉阿茲海默症藥 Kisunla。

歷史沿革

年份里程碑
1876南北戰爭老兵、藥劑化學家 Eli Lilly 上校在印第安納波利斯創立藥廠(1901 年註冊為 Eli Lilly and Company)
1923全球首家量產胰島素(Iletin),與多倫多大學研究團隊合作
1955首家量產沙克小兒麻痺疫苗
1982Humulin 獲批——首個重組 DNA 人胰島素,也是首個生物科技藥物
1987百憂解(Prozac,fluoxetine)獲批——成為重磅抗憂鬱藥
1996Zyprexa(olanzapine)獲批,治精神分裂症與躁鬱症
2003犀利士(Cialis,tadalafil)獲批——成為勃起功能障礙重磅藥
2008以約 $6.5B(65億美元)收購 ImClone Systems,取得癌症藥 Erbitux
2014以 $5.4B(54億美元)收購諾華動物保健業務,併入 Elanco
2017David Ricks 接任執行長
2018動物保健業務 Elanco 上市(9月)
2019以約 $8.0B(80億美元;每股 $235.00 現金,2019年1月7日宣布)收購 Loxo Oncology(2月);完成 Elanco 分拆(3月)
2022Mounjaro(替爾泊肽)獲 FDA 批准治二型糖尿病(5月)
2023Zepbound 獲批治慢性體重管理(11月,美國)
2024Kisunla(donanemab)獲批治早期阿茲海默症(7月,美國);禮來成為全球市值最高藥廠
2025替爾泊肽系列營收 $36.5B(365億美元,佔 56%);市值觸及 $1T(1兆美元,11月),全球首家醫療健康公司
2026Foundayo(orforglipron)——首個口服小分子 GLP-1——獲 FDA 批准治肥胖(4月);第二季營收 $22.97B(229.7億美元,同比 +48%)創紀錄;上調 FY2026 指引至 $85–87B(850–870億美元);宣布在賓州投資 $3.5B(35億美元)建注射劑廠(10月)

競爭地位

  • 全球營收第一大藥廠——FY2025 營收 $65.2B(652億美元),險勝默沙東的 $65.0B(650億美元);光是替爾泊肽系列 $36.5B(365億美元)的年營收,就超過多數中型藥廠整家公司(Drug Discovery Trends,2026年2月)。
  • 腸泌素雙寡頭的一半——GLP-1 市場由禮來與諾和諾德分治。Zepbound 在美國新增品牌肥胖藥處方市佔近七成(70%),Mounjaro 在美國新增二型糖尿病處方市佔逾 55%(禮來 2025 年第四季財報電話會)。
  • 專利跑道——替爾泊肽美國主化合物專利至 2036 年;學名藥廠 2026 年 7 月已遞交提前仿製申請,禮來正提告捍衛。
  • 下一代管線——orforglipron(Foundayo,2026年4月獲批)是首個口服小分子 GLP-1;三重促效劑 retatrutide 與 eloralintide 領軍 36 項三期臨床試驗。
  • 產能即護城河——自 2020 年承諾逾 $55B(550億美元)擴產;小瓶裝降價與 LillyDirect 直銷通路擴大可及性,同時壓低實現價格。
  • 競爭集合——諾和諾德(Wegovy/Ozempic;口服 Wegovy 2025年12月獲 FDA 批准)、安進(MariTide)、輝瑞、Viking、Structure、羅氏/Zealand,以及販售替爾泊肽仿配方的調劑藥房。

財務快照 — FY2025

營收$65.18B(651.8億美元,同比 +45%;FY2024 $45.04B(450.4億美元))
毛利/毛利率$54.1B(541億美元)· 83.0%
營業利潤$26.30B(263億美元)· 利潤率 40.4%
淨利潤$20.64B(206.4億美元)· 淨利率 31.7%(同比 +95%)
稀釋 EPS$22.95(22.95美元,報表)· $24.21(24.21美元,非 GAAP,同比 +86%)
研發費用$13.3B(133億美元,佔營收 20.4%)
經營現金流$16.81B(168.1億美元;FY2024 $8.82B(88.2億美元))
自由現金流約$6.0B(60億美元,經營現金流 $16.81B(168.1億美元) − 資本支出 $10.85B(108.5億美元))
現金及等價物$7.27B(72.7億美元,2025年12月31日)
總債務約$42.5B(425億美元)——淨負債狀態(債務權益比約 1.6 倍)
股息$6.00(6.00美元)/股(同比 +15%)· 已付 $5.38B(53.8億美元)
最新一季(2026 年第二季,截至2026年6月30日)營收 $22.97B(229.7億美元,同比 +48%)· 淨利潤 $7.10B(71億美元)· 稀釋 EPS $7.94(7.94美元)(非 GAAP $8.38(8.38美元))· 毛利率約 86%
來源:禮來 FY2025 Form 10-K(2026年2月申報;會計年度截至2025年12月31日),經 S&P Capital IQ(FT Markets)與 Alpha Spread 的 10-K 明細;2026 年第二季財報(2026年8月5日)。毛利率 83.0% 反映有利的產品組合,部分被實現價格下滑抵銷。

主要風險

  • 單一分子集中——替爾泊肽佔營收 56%。該分子若出現安全性訊號、供應中斷或價格衝擊,超過半家公司受影響。
  • 專利懸崖與學名挑戰——美國主化合物專利至 2036 年,但學名藥廠 2026 年 7 月已遞交提前仿製申請;禮來正在訴訟,敗訴將提前打開王牌產品。
  • 價格壓力——美國實現價格持續下滑(2026 年預期再降低至中十幾個百分點);Medicare/Medicaid 肥胖藥給付協議目標自付每月 $50(50美元),PBM 抽取的返點越來越高。
  • 諾和諾德與下一波——口服 Wegovy 2025年12月獲 FDA 批准;安進 MariTide、輝瑞、Viking 等以差異化機制追趕同一肥胖市場。
  • 調劑藥房——仿配替爾泊肽以價格競爭,遊走於品牌通路之外,已引來 FDA 與禮來的執法關注。
  • Trulicity 萎縮——傳統糖尿病業務 FY2025 下滑 19%,被替爾泊肽蠶食,專利老化後有生物相似藥風險。
  • 產能執行——逾 $55B(550億美元)的擴產計畫吃掉大半經營現金流(FY2025 資本支出 $10.85B(108.5億美元));延誤或超支會封住市場願意付費的上行空間。

對標普500的重要性

禮來是指數第 11 大成分股,權重 1.60%(2026年10月21日)——LLY 單獨波動 1%,標普500 大約動 1.6 個基點;按市值 $1,120B(1.12兆美元,2026年10月16日)是醫療健康板塊第一大公司。在科技主導的指數裡,禮來是醫療板塊的防禦成長錨:板塊風向標,貝塔低(約 0.43),也是市場上最純的肥胖藥週期曝險。

對指數與期權交易者:禮來每季財報(1 月底/4 月/7 月/10 月底)被市場當作 GLP-1 需求、定價與供應的定調,牽動 XLV 與整個醫療板塊;其與諾和諾德的處方市佔數據,是市場能拿到的最高頻腸泌素雙寡頭戰況。

來源與方法

財務、產品、員工、現金/債務禮來 FY2025 Form 10-K(2026年2月申報;會計年度截至2025年12月31日);明細經 S&P Capital IQ(FT Markets)與 Alpha Spread
產品營收拆分FY2025 10-K 產品披露(SEC 申報為本的彙整);Mounjaro/Zepbound 總額已與 2025 年第四季財報(2026年2月4日)交叉核對
最新一季(2026 年第二季)禮來 2026 年第二季財報(2026年8月5日);季度截至2026年6月30日
指數權重與排名Slickcharts 標普500權重,2026年10月21日收盤(任務基線)
市值與板塊排名2026年10月16日快照(SPXSet Top-25 數據集;任務基線)
處方市佔、管線、指引禮來 2025 年第四季財報電話會逐字稿(finviz);FY2026 指引 $85–87B(850–870億美元)營收,經 TipRanks(2026年10月20日)
歷史與公司事實禮來 10-K/10-Q/8-K 申報(經 findstockfast);維基百科公司條目(事實已與申報交叉核對)
LogoSPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。

10年股價K線圖(月K)

Lilly

來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份) · SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · LLY
Data as of Oct 21, 2026 · Financials FY2025 (10-K) · Market data Oct 2026
Previous · Advanced Micro Devices, Inc. (AMD) — XLK Information Technology · S&P 500 Profile |超微半導體公司介紹Next · Berkshire Hathaway Inc. (BRK.B) — XLF Financials · S&P 500 Profile |波克夏公司介紹

Entered 2026-10-23 04:17 · updated 2026-11-14 23:46 · rev 17